Saxonov Serge 4

What Happened Serge Saxonov, CEO of 10x Genomics (TXG), was granted 157,895 restricted stock units (RSUs) on February 26, 2026. The reported acquisition price is $0.00 (code A), reflecting an award rather than a cash purchase; the filing lists no immediate cash value realized. The RSUs convert to one share of Class A common stock per unit upon vesting.

Key Details

• Transaction date: 2026-02-26; Grant type: Award/Grant (code A); Amount: 157,895 RSUs; Reported price: $0.00.
• Vesting: Per footnote, each RSU vests 1/12th on each quarterly anniversary measured from February 21, 2026 — effectively quarterly vesting over 12 quarters (three years), subject to continued service.
• Trust holdings: Footnotes indicate other shares are held by Andromeda Trust, Y/S Descendants' Trust and Y/S Pot Trust, for which Saxonov is trustee (these are existing holdings, not part of this grant).
• Shares owned after the transaction: not specified in the provided Form 4 details.
• Filing: Report filed 2026-03-02 for the 2026-02-26 grant; this appears to be a timely Form 4 filing (within the required 2 business days).

Context RSUs are compensation awards that convert to shares only as they vest; they are not an open-market purchase or sale and do not represent an immediate cash investment by the insider. Such grants are common for executive compensation and should be interpreted as part of pay rather than a direct positive or negative trading signal.